You have no items in your shopping cart.
On Promotion
Elisa Kits Promotion 1
Products on Sale 0
Category
Antibodies 1178
Proteins and Peptides 1121
Small Molecules 284
Tools 65
Assays and Kits 42
Species Host
Rabbit 342
Mouse 234
Human 151
Goat 29
E. coli 28
Mammal 24
Plant 8
Camelus 6
Gallus 1
Tested Applications
ELISA 1023
WB 582
IF 82
IHC 55
NeA 52
Blocking 50
EIA 45
FC 45
Kinetics 33
IHC-P 20
IP 17
LF 13
SDS-PAGE 12
GICA 11
ICC 10
CLIA 8
MS 8
Functional Studies 7
IA 7
In vivo 6
Crystallography 5
Control 4
DOT 4
FA 2
Reactivity
Virus 778
Human 182
Other 54
Mouse 52
Rat 15
Hamster 3
Primate 2
All 1
Predicted Reactivity
Virus 82
Bovine 6
Canine 1
Equine 1
Guinea 1
Mouse 1
Pig 1
Rabbit 1
Rat 1
Zebrafish 1
Conjugation
Unconjugated 983
Biotin 61
HRP 54
AP 24
PE 16
FITC 15
APC 14
Cy3 14
iFluor647 14
AE 7
IRDye800 4
Clonality
Monoclonal 593
Polyclonal 402
Recombinant 173
Matched Antibody
Yes 0
No 2690
Featured Product
Yes 327
Has Publications
Yes 1
No 2689
Search results for: 'SARS-CoV-2'
98.00%
51.9 kDa (predicted); 56.4 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutations L452R, E484Q) (Arg319-Phe541) was expressed with the Fc region of human IgG1 at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.617, B.1.617.1 or B.1.617.3) which emerged in the India. Predicted N terminal: Arg 319
C-Fc
100 μg98.00%
51.9 kDa (predicted); 55.9 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutations K417T, E484K, N501Y) (Arg319-Phe541) was expressed with the Fc region of human IgG1 at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant P.1) which emerged in the Brazil. Predicted N terminal: Ser
C-Fc
100 μg98.00%
46.6 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Nucleocapsid (YP_009724397.2, with mutations D63G, R203M, D377Y) (Met1-Ala419) was expressed with a polyhistidine tag at the N-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.617.2) which emerged in the India. Predicted N terminal: Met
N-His
100 μg98.00%
136.26 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (BA.4/BA.5/BA.5.2) Spike S1+S2 (YP_009724390.1, with mutations F817P, A892P, A899P, A942P, K986P, V987P, T19I, L24del, P25del, P26del, A27S, H69del, V70del, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K and furin cleavage site mutants) expressed with the bacteriophage T4 fibritin and a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant BA.4/BA.5/BA.5.2). Predicted N terminal: Val 16
C-His
100 μg98.00%
26.72 kDa (predicted); 35.43 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (BA.2.9.1 and BA.2.13) Spike RBD (YP_009724390.1, with mutations G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452M, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H)(Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant BA.2.9.1 and BA.2.13). Predicted N terminal: Arg 319
C-His
100 μg98.00%
76.40 kDa (predicted); 102.93 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (BA.2.12.1) Spike S1 (YP_009724390.1, with mutations T19I, L24S, del25-27, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452Q, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H) (Met1-Arg685) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant BA.2.12.1). Predicted N terminal: Val 16
C-His
100 μg98.00%
26.72 kDa (predicted); 37.06 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (BA.2.12.1) Spike RBD (YP_009724390.1, with mutations G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452Q, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H)(Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant BA.2.12.1). The purified protein was biotinylated in vitro. Predicted N terminal: Arg 319
C-His
20 μg98.00%
34.09 kDa (predicted); 50.74 kDa (reducing conditions)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (BA.2) Spike S1 NTD (YP_009724390.1, with mutation T19I, L24S, del25-27, G142D, V213G) (Met1-Ser305) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant BA.2). Predicted N terminal: Val 16
C-His
100 μg98.00%
46.37 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (BA.4) Nucleocapsid (YP_009724397.2, with mutation P13L, ERS31-33del, P151S, R203K, G204R, S413R) (Met1-Ala419) was expressed with a polyhistidine tag at the N-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant BA.4). Predicted N terminal: Met
N-His
100 μg98.00%
26.72 kDa (predicted); 35.86 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (BA.2.12.1) Spike RBD (YP_009724390.1, with mutations G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452Q, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H)(Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant BA.2.12.1). Predicted N terminal: Arg 319
C-His
100 μg